Thu 28 Jan 2021
DORC announces Health Canada approval of TissueBlue™ for Staining of the ILM During Vitreoretinal Surgery – the first Health Canada approved product for this indication. | Press Release
DORC announces Health Canada approval of TissueBlue™ for Staining of the ILM During Vitreoretinal Surgery – the first Health Canada approved product for this indication.
Zuidland, NETHERLANDS – DORC is proud to announce that it has received notification from Health Canada that the application for TissueBlue™ (Brilliant Blue G Ophthalmic Solution) 0.025% has been approved and will be available from later in 2021 via INNOVAMED, DORC’s local distributor partner. News follows almost exactly 1 year after TissueBlue™ received FDA approval, since FDA approval DORC estimate TissueBlue™ has been used in over 15,000 retina procedures in the USA*.
TissueBlue™ (Brilliant Blue G Ophthalmic Injection) is the first dye approved by Health Canada for use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane (ILM) . Approval by Health Canada follows one year after approval by the FDA for use in the USA.
The further highlights of this release are as follows:
- TissueBlue™ was approved by the FDA in December 2019 and sales started in April 2020. Since launch TissueBlue™ has been used in over 15,000 vitrectomy procedures in the USA*
- 96% of users would recommend TissueblueTM to their colleagues – confirmed in evaluation surveys completed by 49 US retina surgeons following use of their first sample of TissueblueTM **
- The formulation of TissueblueTM will be the first ILM stain available in Canada to feature pharmaceutical grade dye material
- TissueBlue™ will also be the first ILM stain available in Canada in a sterile, prefilled syringe for improved ease of use – 44/49 surgeons rated this feature as ‘Excellent’ in the US surgeon evaluations**
- TissueBlue™ will provide a safe and effective replacement to ICG and other compounded or off- label staining agents previously used in Canada***
- DORC expects to start shipping TissueBlue™ to customers in late 2021 after finalizing technical product filing requirements for Health Canada.
- TissueBlue™ will be distributed by DORC’s local partner, INNOVAMED who already distribute the DORC EVA™ phacovitrectomy system, instruments and VisionBlue™ the only Cataract stain approved in Canada.
Commenting on the launch, David Chow, MD, Assistant Professor St Michael’s Hospital, said, “Health Canada approval of TissueBlue™ is an important milestone for retina surgeons in Canada. Retina specialists will welcome the opportunity to use an approved ILM dye that combines consistent, high quality staining performance with a long track-record of safe use worldwide in over 350,000 surgeries since launch. A further benefit is the convenience and added security of its packaging in a sterile, prefilled syringe, avoiding the need for mixing the dye prior to use. I am excited to have the opportunity to use this stain in my macular surgery.”
“Following one year from FDA approval, we are delighted to bring TissueBlue™ to Canadian retina surgeons.” commented Pierre Billardon, CEO DORC International. “Experience from 15,000 surgical procedures and feedback from users of TissueBlue™ confirms the surgical benefits of TissueBlue™ and also highlights that surgeons prefer operating with a pharmaceutical grade, approved dye. This approval is the result of several years of intensive work from cross functional teams within DORC and we are also very grateful for the support we have received from the Canadian Retina Society and retina surgeons in the US.”
TissueBlue™ is used to selectively stain the internal limiting membrane (ILM) which forms the inner layer of the retina. Cellular proliferation on the ILM can lead to the formation of vision-impairing epiretinal membranes (ERM) and macular holes. While the removal of the ILM can relieve symptomatic macular distortion caused by ERMs and macular holes, the transparent nature of the ILM makes it difficult to visualize and peel. Brilliant Blue G Ophthalmic Injection is applied onto the inner retinal surface, enabling the ILM to be clearly stained and distinguished from unstained retina, thereby facilitating removal.
For further information please visit www.tissueblue.com
For contact on local availability – please contact:
* – DORC US Sales of TissueBlue and Global Sales data for ILM Blue – available on file
** – Results of 49 surgeon evaluations collected from US retina surgeons sampling TissueBlue – available on file
*** – PAT Survey 2017 – ‘What adjuvant do you prefer as an aid in ERM and/or ILM peeling?’ 2017 PAT survey of 1077 surgeons in the US and Globally